110 related articles for article (PubMed ID: 20812163)
1. ["The Lantus case": and yet it does move (or not?)].
Schöffski O
Dtsch Med Wochenschr; 2010 Sep; 135(36):1755-6. PubMed ID: 20812163
[No Abstract] [Full Text] [Related]
2. [My quality of life has increased with Lantus].
Euler H
Lakartidningen; 2004 Sep; 101(39):3015; discussion 3016. PubMed ID: 15493645
[No Abstract] [Full Text] [Related]
3. [Are the short-acting insulin analogs superfluous?].
Arand M
MMW Fortschr Med; 2006 Mar; 148(11):17. PubMed ID: 16612957
[No Abstract] [Full Text] [Related]
4. [Short acting insulin analogues for type 2 diabetes. Unnecessary additional expenditure or valuable added benefit? Interview by Böhm Sanja].
Hess R; Kerner W
Dtsch Med Wochenschr; 2006 Oct; Suppl 1():36-7. PubMed ID: 17595817
[No Abstract] [Full Text] [Related]
5. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
6. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
[TBL] [Abstract][Full Text] [Related]
7. ["The Lantus Case": What is the benefit of health economics?].
Schöffski O
Dtsch Med Wochenschr; 2010 May; 135(20):1033-5. PubMed ID: 20461663
[No Abstract] [Full Text] [Related]
8. Insulin glargine for type 2 diabetes.
Hemraj F; Garces K
Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441
[TBL] [Abstract][Full Text] [Related]
9. [Basal insulin in discussion--clinical and health economics aspects].
Middeke M
Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S99; discussion S124-6. PubMed ID: 18686223
[No Abstract] [Full Text] [Related]
10. [Costs of antihyperglycemic treatment and consumables and treatment satisfaction in patients with type 2 diabetes].
Schröder J; Kerner W
Dtsch Med Wochenschr; 2009 Nov; 134(46):2355; author reply 2355-6. PubMed ID: 19894207
[No Abstract] [Full Text] [Related]
11. [Current cost analysis in the management of diabetes mellitus].
Oberender P
Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S110-4; discussion S124-6. PubMed ID: 18686219
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
Levin P
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
[TBL] [Abstract][Full Text] [Related]
13. [Prevention and early therapy play too minor a role in our health care system].
Rothe HJ
Med Klin (Munich); 2003 Oct; 98 Suppl 1():22-3. PubMed ID: 14694840
[No Abstract] [Full Text] [Related]
14. [Economics under scrutiny - experts discuss long acting insulin analogs].
Pflege Z; 2011 Jan; 64(1):58. PubMed ID: 21305792
[No Abstract] [Full Text] [Related]
15. [The first inhalational insulin. Which patients really profit from it? (interview by Dr. D. Einecke)].
Schumm-Draeger PM
MMW Fortschr Med; 2007 Jan; 149(1-2):16-7. PubMed ID: 17632858
[No Abstract] [Full Text] [Related]
16. Clinical practice guidelines and conflict of interest.
CMAJ; 2005 Nov; 173(11):1297, 1299. PubMed ID: 16301688
[No Abstract] [Full Text] [Related]
17. [Lantus is superior in BOT (basic oral therapy) to standard mixed insulin].
Krankenpfl J; 2004; 42(5-6):172. PubMed ID: 15527234
[No Abstract] [Full Text] [Related]
18. Whither inhaled insulin?
Young B
Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):413. PubMed ID: 16932324
[No Abstract] [Full Text] [Related]
19. Costs Associated With Using Different Insulin Preparations.
Tylee T; Hirsch IB
JAMA; 2015 Aug; 314(7):665-6. PubMed ID: 26284715
[No Abstract] [Full Text] [Related]
20. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
